ACEA Biosciences
Wayne Ouyang has a diverse work experience in various scientific and research roles. Wayne started their career as a Postdoctoral Fellow & Research Fellow at Weill Medical College of Cornell University in 2000 and continued in this position until 2005. From 2005 to 2006, they worked as an Electrophysiologist at Impulse Monitoring. In 2006, they returned to Weill Medical College of Cornell University as a Sr Research Associate and stayed until 2007. Following that, they joined ALA Scientific Instrument Inc as an Application Scientist and Product Manager from 2007 to 2009. From 2009 onwards, they worked at ACEA Biosciences as a Sr Application Scientist and Product Manager.
Wayne Ouyang obtained their Master of Science degree in Neurophysiology from Shanxi Medical University, where they attended from 1992 to 1995. Wayne then pursued their doctoral studies in Neurobiology at Fudan University from 1997 to 2000, earning a Ph.D. degree.
ACEA Biosciences
ACEA Biosciences is a biotechnology company founded in 2002 and headquartered in San Diego, California. ACEA is a pioneer in the development and commercialization of high-performance microelectronic systems for cell-based assays. ACEA has a world-class manufacturing operation centered in Hangzhou, Zhejiang Province, China.The Life TechnologyBusiness Unit developed ACEA’s proprietary real-time, label-free cell-based assay technology and launched the first product in 2004. The technology has been marketed globally under the xCELLigence brand. There are over 800 customers worldwide, and over 350 peer-reviewed publications using the xCELLigence technology.The newly launched iCELLigence instrument with wireless connectivity makes this innovative technology affordable to all users. In addition to the Life Technology Business Unit, ACEA also has a Therapeutics Business Unit which was launched in 2005.ACEA Therapeutics is focused on oncology drug discovery and development, leveraging the platform biosensor technology and proprietary small molecule library (> 1 million compounds) to bring novel therapeutics into the clinic. ACEA currently has one program in phase II clinical trials in China and numerous early clinical and preclinical leads. With its international reach, ACEA Biosciences continues to work closely with scientists throughout the world to bring innovation to the R&D and health care industries.